News About <![CDATA[AM.ETF PACIF.JAP.]]> News About en-us <![CDATA[UPDATE 1-Cephalon gets subpoena from U.S. DOJ]]> <![CDATA[EU mergers and takeovers (Sept 28)]]> <![CDATA[REFILE-UPDATE 1-Valeant offers C$88 mln for Afexa, tops Paladin]]> <![CDATA[Valeant to offer C$88 mln for Afexa, tops Paladin]]> <![CDATA[EU mergers and takeovers (Sept 23)]]> <![CDATA[Teva offers EU watchdog concessions for Cephalon buy]]> <![CDATA[Cephalon sues Sandoz over Fentora cancer drug]]> <![CDATA[EU mergers and takeovers (Sept 16)]]> <![CDATA[EU mergers and takeovers (Sept 14)]]> <![CDATA[UPDATE 2-Valeant tops Paladin with C$76 mln bid for Afexa]]> <![CDATA[EU mergers and takeovers (Aug 29)]]> <![CDATA[UPDATE 3-Generic threat to Valeant drug sends shares reeling]]> <![CDATA[UPDATE 1-Cephalon quarterly profit falls short of estimates]]> <![CDATA[UPDATE 5-Meda shares jump on Valeant bid speculation]]> <![CDATA[UPDATE 3-Valeant makes approach for drugmaker Meda]]> <![CDATA[U.S. stock index futures signal early bounce]]> <![CDATA[UPDATE 1-FTC seeks more information on Teva, Cephalon deal]]> <![CDATA[UPDATE 1-Canada's Valeant Pharma to buy Sanitas for $443 mln]]> <![CDATA[UPDATE 2-Teva Q1 profit up on higher European sales]]> <![CDATA[US STOCKS-Futures lower as dollar gain hits commodities]]> <![CDATA[RPT-DEALTALK-CEOs bare teeth and go hostile]]> <![CDATA[PRESS DIGEST - Financial Times - May 3]]> <![CDATA[DEALTALK-CEOs bare teeth and go hostile]]> <![CDATA[US STOCKS-Wall St flat after initial rise on bin Laden death]]> <![CDATA[US STOCKS-Stocks edge higher after US forces kill bin Laden]]> <![CDATA[UPDATE 1-Teva to acquire Cephalon, topping Valeant]]> <![CDATA[UPDATE 1-Glass Lewis argues against Cephalon board change]]> <![CDATA[UPDATE 1-Valeant adds former BlackRock exec to proposed slate]]> <![CDATA[REFILE-UPDATE 2-Synthes confirms in deal talks with J&J]]> <![CDATA[UPDATE 1-J&J in talks to buy Synthes for $20 bln-source]]> <![CDATA[UPDATE 3-J&J in talks to buy Synthes for $20 bln-WSJ]]> <![CDATA[UPDATE 1-Taconic Capital says owns 7.46 pct of Cephalon]]> <![CDATA[Canadian M&A activity surges in first quarter]]> <![CDATA[UPDATE 1-Cephalon files offer document for ChemGenex]]> <![CDATA[UPDATE 3-Valeant could raise Cephalon bid if it sees books]]> <![CDATA[UPDATE 1-Cephalon urges investors to support current board]]> <![CDATA[UPDATE 1-Valeant looks to replace Cephalon board]]> <![CDATA[US STOCKS-Wall Street climbs on job expectations]]> <![CDATA[Cephalon shares surge above Valeant bid price]]> <![CDATA[UPDATE 3-Valeant seeks to buy Cephalon for $5.7 bln]]> <![CDATA[UPDATE 1-Cephalon offers $231 mln takeover of ChemGenex]]> <![CDATA[Cephalon receives subpoena related to Fentora]]> <![CDATA[UPDATE 1-Lundbeck signs commercial deal with Cephalon]]> <![CDATA[Some pharmaceutical makers may be targets -Barron's]]> <![CDATA[UPDATE 1-Cephalon's Nuvigil sails through post-approval study]]> <![CDATA[UPDATE 1-Cephalon drops development of Nuvigil for jet lag]]> <![CDATA[UPDATE 1-Cephalon CEO dies at age of 57 after medical leave]]> <![CDATA[UPDATE 1-Cephalon, Mesoblast in stem cell development deal]]> <![CDATA[UPDATE 1-Cephalon boosts 2010 earnings view after strong Q3]]> <![CDATA[UPDATE 1-Cephalon says settles Amrix patent dispute]]>